Disease considerations for the test include a custom set of genetic sequences associated in peer-reviewed literature with the following conditions:
- Addison’s disease (16 SNP's)
- Anemia (25 SNP's)
- Asthma (11 SNP's and 3 expression)
- Atherosclerosis (72 SNP's and 8 expression monitor)
- Autism (23 SNP's and 1 expression monitor)
- Breast Cancer (34 SNP's and 10 expression)
- Estrogen Metabolism (exact # can not be specified, category still in development)
- Grave’s disease (34 SNP's and 2 expression) hormone replacement therapy (7 SNP's and 10 expression)
- Major Histocompatibility Complex (MHC) (47 expression)
- Longevity/Brevity (depending on how you wish to view) (36 SNP's and 5 expression)
- Systemic Lupus Erythematosus (22 SNP's)
- Multiple Sclerosis (40 SNP's and 50 expression)
- Obesity (44 SNP's and 7 expression)
- Osteoarthritis (55 SNP's and 9 expression)
- Prostate Cancer (30 SNP's and 9 expression)
- Type 2 Diabetes (72 SNP's and 16 expression)
These numbers (in parentheses) indicate the number of calls (yes/no) that will be made according to the test design. The number of polymorphic variants for SNP's/Insertion/ Deletions is twice the number indicated.
This nucleic acid array is comprised of probe sequences isolated to detect regions within a given gene that most effectively indicate expression levels and that represent polymorphic sections indicating which sequence from the genome an individual is actually expressing.
The nucleic acid sequences deemed present in the amplified fragments of cells isolated from standard blood draw and/or disease affected tissue, will be detected by hybridizing the amplified fragments to the array and analyzing a hybridization pattern resulting from the hybridization.
A developed program for formatting the output includes pertinent information provided as an abbreviated print-out with results and as a CD with access to all of the extended information provided through the test.
